Richard William Scalzo Sells 2,588 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYNGet Free Report) SVP Richard William Scalzo sold 2,588 shares of the stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $28.27, for a total value of $73,162.76. Following the sale, the senior vice president now directly owns 116,695 shares of the company’s stock, valued at approximately $3,298,967.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Richard William Scalzo also recently made the following trade(s):

  • On Monday, March 11th, Richard William Scalzo sold 2,672 shares of Dyne Therapeutics stock. The stock was sold at an average price of $25.28, for a total transaction of $67,548.16.
  • On Thursday, March 7th, Richard William Scalzo sold 2,273 shares of Dyne Therapeutics stock. The shares were sold at an average price of $25.85, for a total transaction of $58,757.05.
  • On Thursday, February 29th, Richard William Scalzo sold 3,429 shares of Dyne Therapeutics stock. The stock was sold at an average price of $27.50, for a total value of $94,297.50.

Dyne Therapeutics Trading Down 3.7 %

Shares of NASDAQ DYN opened at $27.68 on Friday. The firm’s 50 day moving average price is $26.58 and its 200-day moving average price is $19.89. Dyne Therapeutics, Inc. has a 52-week low of $6.40 and a 52-week high of $30.27.

Dyne Therapeutics (NASDAQ:DYNGet Free Report) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.81) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.81). As a group, research analysts expect that Dyne Therapeutics, Inc. will post -3.1 earnings per share for the current year.

Institutional Trading of Dyne Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wetzel Investment Advisors Inc. purchased a new position in shares of Dyne Therapeutics during the 1st quarter worth $28,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Dyne Therapeutics by 58.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,379 shares of the company’s stock worth $75,000 after purchasing an additional 3,092 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Dyne Therapeutics by 95.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 9,310 shares of the company’s stock valued at $83,000 after purchasing an additional 4,552 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Dyne Therapeutics by 355.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock valued at $94,000 after purchasing an additional 5,541 shares during the period. Finally, Principal Financial Group Inc. increased its position in Dyne Therapeutics by 10.7% in the third quarter. Principal Financial Group Inc. now owns 15,229 shares of the company’s stock worth $136,000 after buying an additional 1,476 shares in the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on DYN. Chardan Capital reaffirmed a “buy” rating and issued a $31.00 price target on shares of Dyne Therapeutics in a research note on Monday, May 6th. Oppenheimer reaffirmed an “outperform” rating and set a $47.00 target price on shares of Dyne Therapeutics in a research note on Monday, May 6th. Stifel Nicolaus increased their price target on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of Dyne Therapeutics in a report on Friday, May 3rd. Finally, Piper Sandler upped their target price on Dyne Therapeutics from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.75.

Get Our Latest Research Report on DYN

Dyne Therapeutics Company Profile

(Get Free Report)

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Featured Articles

Insider Buying and Selling by Quarter for Dyne Therapeutics (NASDAQ:DYN)

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.